Immuron US DoD Naval Medical Research Center Submits IND
Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical trials to be conducted. One trial will ...
Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical trials to be conducted. One trial will ...
MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment ...
MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment ...